0001628280-23-010574.txt : 20230404 0001628280-23-010574.hdr.sgml : 20230404 20230404160618 ACCESSION NUMBER: 0001628280-23-010574 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230403 ITEM INFORMATION: Cost Associated with Exit or Disposal Activities ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230404 DATE AS OF CHANGE: 20230404 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NGM BIOPHARMACEUTICALS INC CENTRAL INDEX KEY: 0001426332 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38853 FILM NUMBER: 23797341 BUSINESS ADDRESS: STREET 1: 333 OYSTER POINT BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-243-5555 MAIL ADDRESS: STREET 1: 333 OYSTER POINT BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 8-K 1 ngm-20230403.htm 8-K ngm-20230403
FALSE000142633200014263322023-04-032023-04-03

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
___________________
FORM 8-K
___________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 3, 2023
___________________
NGM Biopharmaceuticals, Inc.
(Exact name of Registrant as Specified in Its Charter)
___________________
Delaware001-3885326-1679911
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
333 Oyster Point Boulevard
South San Francisco, CA 94080
(Address of principal executive offices including zip code)
(650) 243-5555
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
___________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): 
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: 
Title of Each Class
Trading
Symbol(s)
Name of Each Exchange on which Registered
Common Stock, par value $0.001 per shareNGMThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 2.05    Costs Associated with Exit or Disposal Activities.
On April 3, 2023, the Board of Directors (the “Board”) of NGM Biopharmaceuticals, Inc. (the “Company”) approved a restructuring of the Company's workforce, or the restructuring, pursuant to which the Company’s workforce will be reduced by 75 people, or approximately 33% of the Company’s existing headcount. The restructuring was communicated to employees on April 4, 2023. The Company estimates that it will incur approximately $5.0 million in restructuring charges in connection with the restructuring, consisting of (i) approximately $4.5 million in cash-based expenses related to employee severance and notice period payments, benefits and related costs, and (ii) approximately $0.5 million in non-cash stock-based compensation expense related to the vesting of share-based awards. The Company expects that the majority of the restructuring charges will be incurred in the second quarter of 2023 and that the execution of the restructuring, including cash payments, will be substantially complete by the end of the second quarter of 2023.
The estimates of the charges and cash expenditures that the Company expects to incur in connection with the restructuring, and the timing thereof, are subject to a number of assumptions and actual amounts may differ materially from estimates. In addition, the Company may incur other charges or cash expenditures not currently contemplated due to unanticipated events that may occur, including in connection with the implementation of the restructuring.
Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On April 3, 2023, Jin-Long Chen, Ph.D. resigned as Chief Scientific Officer of the Company, and as a member of the Board, in each case effective as of April 4, 2023. The Board has accepted Dr. Chen’s resignation and is grateful for his many contributions to the Company that he founded in 2008.
Item 7.01    Regulation FD Disclosure.
Cash Sufficiency Forecast
On April 4, 2023, the Company announced that, in connection with the implementation of the restructuring, the Company believes that its existing cash, cash equivalents and short-term marketable securities will be sufficient to fund its operations into the second quarter of 2025. The Company has based this estimate on plans and assumptions that may prove to be insufficient or inaccurate (for example, with respect to anticipated costs, timing or success of certain activities), and the Company could utilize its available financial resources sooner than it currently expects. In addition, the foregoing forecast of the period of time through which the Company’s financial resources will be adequate to support its operations is a forward-looking statement that involves risks and uncertainties, and actual results could differ materially as a result of a number of factors, including the factors referenced under “Forward-Looking Statements” below.
Email from Chief Executive Officer
On April 4, 2023, David J. Woodhouse, Ph.D., Chief Executive Officer of the Company, sent an email regarding the restructuring and related workforce reduction to the Company’s employees. The text of the email is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
The information furnished in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Forward-Looking Statements
Statements contained in this Current Report on Form 8-K, including in Exhibit 99.1 hereto, regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believes,” “estimates,” “expects,” “focused,” “continuing to,” “seeking,” “will” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These statements include those related to: the costs, timing and financial impact of the restructuring; the Company remaining an integrated research and development organization following the restructuring, focused on investing in its discovery engine to produce the next generation of new program candidates and developing it solid-tumor oncology portfolio to clinical proof-of-concept; the sufficiency of the Company cash resources to fund its operations: the Company extending its cash runway and the timing thereof, including for long enough to put the Company in a position to generate meaningful clinical data from its solid tumor oncology product candidates while continuing to invest in its discovery efforts and to otherwise arrive at a more sustainable cash burn rate; the Company’s strategy, including with respect to business development transactions; and


other statements that are not historical fact. Because such statements deal with future events and are based on the Company’s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of the Company could differ materially from those described in or implied by the statements in this Current Report on Form 8-K. These forward-looking statements are subject to risks and uncertainties, including, without limitation, risks and uncertainties associated with: impediments to the Company’s ability to execute the restructuring as currently contemplated; the actual charges associated with the restructuring being higher than anticipated or changes to the assumptions on which the estimated charges associated with the restructuring are based; the Company’s ability to achieve projected cost savings in connection with the restructuring; unintended consequences from the restructuring that impact the Company’s business; the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success; risks related to failure or delays in successfully initiating, enrolling, reporting data from or completing clinical studies; the Company’s ability to identify and engage third-party partners for potential future collaboration, out licensing, partnering or other business development arrangements, if any, and its ability to attract such partners; the time-consuming and uncertain regulatory approval process; the sufficiency of the Company’s cash resources and anticipated cash runway, including the risk that the Company could utilize its available capital resources sooner than it currently expects, and the Company’s need for additional capital; macroeconomic conditions (such as the impacts of the ongoing COVID-19 pandemic and the conflict between Russia and Ukraine, global economic slowdown, increased inflation and rising interest rates); and other risks and uncertainties affecting the Company and its development programs, including those discussed in the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the United States Securities and Exchange Commission (the “SEC”) on February 28, 2023 and subsequent filings and reports that the Company makes from time to time with the SEC. Except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons if actual results differ materially from those anticipated in the forward-looking statements.
Item 9.01    Financial Statements and Exhibits.
(d)    Exhibits
Exhibit No.Description
99.1
104Cover Page Interactive Data File (embedded within the Inline XBRL document)



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 
 NGM Biopharmaceuticals, Inc.
Dated: April 4, 2023By:/s/ David Woodhouse
David J. Woodhouse, Ph.D.
Chief Executive Officer

 EX-99.1 2 ngm-20230403xexx991.htm EX-99.1 Document

Exhibit 99.1
April 4, 2023
Subject Line: Important Business Updates


Dear Explorers:
This morning I am announcing a difficult, but necessary, decision. NGM is undergoing a restructuring, which includes reducing the size of our NGM team by 75 of our friends and colleagues, or approximately one-third of our existing footprint. All functions are impacted by this restructuring – G&A, research and development. NGM remains an integrated research and development organization, focused on investing in our discovery engine to produce the next generation of new program candidates and development of our solid-tumor oncology portfolio to clinical proof-of-concept.
There is no good way to communicate the decision to all of you whose jobs are being eliminated. In an effort to minimize anxiety and waiting, all employees will receive an email shortly. For those whose roles are being eliminated, we will be reaching out to you individually as quickly as possible this morning to meet with you to share the details of your transition and separation package before providing you with more comprehensive written materials to begin to answer any questions you may have. For those of you whose roles are not being eliminated, you will receive an email reflecting that information.
I hope you all know this decision was taken with great deliberation and thought. While this is one of the most challenging decisions that we have had to make in NGM’s 15-year history, I recognize that the outcome of this decision will also be challenging for our departing colleagues. There will be a road of healing ahead, and to begin this journey with you all, I would like to share some information regarding how we got here.
How The Decision Was Reached
Raising capital has become increasingly difficult for companies in our industry over the last couple of years. In this regard, while we had hoped to be able to pursue a significant financing on the back of positive clinical data in 2022 following CATALINA, the clinical data we announced unfortunately did not support pursuing such a financing at that time.
As a result, and in light of our current strategy, we must take steps to reduce our operating expenses and extend our cash runway for long enough to put us in a position to generate meaningful clinical data from our solid tumor oncology product candidates while continuing to invest in our discovery efforts. Management, together with the Board of Directors, explored many avenues to see how we could achieve a cash runway extension of up to two years and ultimately determined that this restructuring was necessary and in the best interests of NGM at this time. Ongoing efforts to reduce our other operational expenses will not be sufficient on their own. And while our strategy continues to include seeking business development transactions for one or more of our programs, even if we were to succeed in securing a deal or deals this year, we believe a restructuring would still be necessary to arrive at a more sustainable cash burn rate. In other words, we came to this decision when we believed it was required to enable us to continue to invest in our critical discovery research work and advance our development programs with a narrowed focus on oncology to fulfill that mission for the benefit of patients. I understand how disappointing this is and I want to emphasize that I take full responsibility for leading us here today.
Our talented team at NGM is the foundation and the core of our company. This restructuring and the jobs eliminated today are not a reflection of you or your contributions to NGM. Each and every one of you, regardless of whether you’re departing or remaining, has had an invaluable impact on our organization, and I thank you for your commitment.
Founder Departure
In a separate but also impactful development, Jin-Long Chen, our founder and Chief Scientific Officer, has decided to move on from NGM after 15 years of dedicating his heart and soul to the company and its mission. While the timing of this restructuring makes the announcement of this departure even more jarring than it might otherwise be, in many ways, it is fitting. Over the past few years, Jin-Long has built a scientific leadership team more than capable of continuing our track record of innovation. With Jin-Long’s departure, I am pleased to announce that Dan Kaplan will be taking on the role of Chief Scientific Officer at a time when we are re-affirming our commitment to research at NGM. We will miss Jin-Long immeasurably and are grateful for all he has done for NGM.
Additional Information for Employees Departing in the Restructuring
I am committed to each of you being treated in a respectful manner during your transition. We are offering separation packages to departing employees which include a combination of continuation of salary and a severance payment covering at least three months and continued healthcare paid for by NGM through the end of July. We will also provide career transition support, including up to six months of prepaid support from a third-party outplacement service provider and compiling a resume book that NGM will share with a broad network of biotech companies.


Most importantly, I personally want to thank each of you for your service and contributions to NGM. The company would not be what it is today without your dedication and commitment to our culture and mission.
Additional Information for Go-Forward Employees
Please be patient this morning as we focus our time and attention on meeting with your colleagues whose positions have been eliminated. You will receive additional information from your team leader about a meeting this afternoon to talk more about these decisions, what it will mean for us going forward and to provide a chance for us to process this together. I will also hold an All-Hands meeting tomorrow morning at 9:00am PDT. If you have questions you would like to ensure are addressed at tomorrow’s All-Hands, there will be a link to submit questions in your invitation.
I understand that these next few weeks will be challenging—please be compassionate to those departing the company and take time to celebrate their contributions to NGM, science and the industry overall. And take the time that will inevitably be necessary to process this significant shift, reaching out to your colleagues, manager and the management team if that would be helpful.
I want to emphasize that we did not make this decision lightly, and only after determining that, for the long-term success of NGM and to make possible our dream of bringing medicines to patients, this restructuring is necessary at this time. I am profoundly saddened that NGM has arrived at this moment and for the effect the restructuring will have on each of you.
We will rebuild from here, but in the meantime, if you have any questions, please reach out to me, an EC member, or a member of the People Team.
Sincerely,
David


 EX-101.SCH 3 ngm-20230403.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 ngm-20230403_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Written Communications Written Communications City Area Code City Area Code Cover [Abstract] Title of 12(b) Security Title of 12(b) Security Document Type Document Type Amendment Flag Amendment Flag Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Document Period End Date Document Period End Date Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 5 ngm-20230403_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover
Apr. 03, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Apr. 03, 2023
Entity Registrant Name NGM Biopharmaceuticals, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-38853
Entity Tax Identification Number 26-1679911
Entity Address, Address Line One 333 Oyster Point Boulevard
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code 650
Local Phone Number 243-5555
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol NGM
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001426332
XML 7 ngm-20230403_htm.xml IDEA: XBRL DOCUMENT 0001426332 2023-04-03 2023-04-03 false 0001426332 8-K 2023-04-03 NGM Biopharmaceuticals, Inc. DE 001-38853 26-1679911 333 Oyster Point Boulevard South San Francisco CA 94080 650 243-5555 false false false false Common Stock, par value $0.001 per share NGM NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://ngmbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ngm-20230403.htm ngm-20230403.xsd ngm-20230403_lab.xml ngm-20230403_pre.xml ngm-20230403xexx991.htm http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ngm-20230403.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "ngm-20230403.htm" ] }, "labelLink": { "local": [ "ngm-20230403_lab.xml" ] }, "presentationLink": { "local": [ "ngm-20230403_pre.xml" ] }, "schema": { "local": [ "ngm-20230403.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ngm", "nsuri": "http://ngmbio.com/20230403", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ngm-20230403.htm", "contextRef": "i75d32857551f446ca87927df8069c5d1_D20230403-20230403", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://ngmbio.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ngm-20230403.htm", "contextRef": "i75d32857551f446ca87927df8069c5d1_D20230403-20230403", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ngmbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ngmbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ngmbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ngmbio.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ngmbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ngmbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ngmbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ngmbio.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ngmbio.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ngmbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ngmbio.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ngmbio.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ngmbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ngmbio.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ngmbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ngmbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ngmbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ngmbio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ngmbio.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ngmbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ngmbio.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ngmbio.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001628280-23-010574-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-23-010574-xbrl.zip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end